Pancreatic Cancer Research

ResearcherUniversitat de ValènciaActive in the last 2 years

Marisol Huerta

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8523-6711; OpenAlex author ID A5004114407, A5068118959. Sources: OpenAlex.

Their work

Papers
7
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 7

  1. Finding More in Less: Precision Medicine for Pancreatic Cancer Using Residual Cytology Samples. Co-author DOI 10.1111/cyt.70055↗
  2. Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic … Co-author DOI 10.1016/j.esmoop.2025.105122↗
  3. ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and identifies actionable alterations in fast pr… Co-author DOI 10.1016/j.trsl.2024.05.003↗
  4. Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. Co-author DOI 10.3390/cancers13050994↗
  5. Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre. Co-author DOI 10.1136/esmoopen-2020-000929↗
  6. Borderline resectable pancreatic cancer. Challenges and controversies. Co-author DOI 10.1016/j.ctrv.2018.06.006↗
  7. Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propen… Co-author DOI 10.1155/2018/2373868↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrès M.R. Cervantes · 7 shared papers, 2018–2026 · strength 0.94
  2. Luis Sabater-Orti · 5 shared papers, 2018–2026 · strength 0.68
  3. Clara Alfaro‐Cervelló · 4 shared papers, 2020–2026 · strength 0.60
  4. Marina Garcés‐Albir · 4 shared papers, 2018–2024 · strength 0.44
  5. Susana Roselló · 4 shared papers, 2018–2024 · strength 0.44
  6. Noelia Tarazona · 3 shared papers, 2020–2024 · strength 0.37
  7. Dimitri Dorcaratto · 3 shared papers, 2018–2024 · strength 0.32
  8. Raquel Antón‐Peñalver · 1 shared paper, 2026 · strength 0.24
  9. Alexander Grenander Raufi · 1 shared paper, 2025 · strength 0.19
  10. Steven Francis Powell · 1 shared paper, 2025 · strength 0.19
  11. Benedito A. Carneiro · 1 shared paper, 2025 · strength 0.19
  12. Ludimila L. Cavalcante · 1 shared paper, 2025 · strength 0.19
  13. Devalingam Mahalingam · 1 shared paper, 2025 · strength 0.19
  14. Andrew L. Coveler · 1 shared paper, 2025 · strength 0.19
  15. Anwaar Saeed · 1 shared paper, 2025 · strength 0.19
  16. Jordan D. Berlin · 1 shared paper, 2025 · strength 0.19
  17. Vaibhav Sahai · 1 shared paper, 2025 · strength 0.19
  18. Mary F. Mulcahy · 1 shared paper, 2025 · strength 0.19
  19. Maider Ibarrola‐Villava · 1 shared paper, 2021 · strength 0.12
  20. Angelica Petrillo · 1 shared paper, 2018 · strength 0.07
  21. Teresa Troiani · 1 shared paper, 2018 · strength 0.07
  22. Luca Pompella · 1 shared paper, 2018 · strength 0.07
  23. Ferdinando De Vita · 1 shared paper, 2018 · strength 0.07
  24. Jole Ventriglia · 1 shared paper, 2018 · strength 0.07
  25. Floriana Morgillo · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.